Covering the BioBay Investor Forum 2008, Interfax reported the increasing importance of patented technologies in China biopharma, and it predicted the Yangtze River Delta would soon house the largest collection of clinical research facilities in the world. BusinessWeek published an overview of the sea turtle phenomenon. US-based Provid Pharma formed a CRO alliance with Acesys Pharmatech of China; Tianyin Pharma released very solid unaudited results for fiscal 2008; Tongjitang Chinese Medicines announced a $20 million stock buyback; China Sky One Medical said it has submitted 26 new drugs for approval; Tianyin Pharma received approval for a TCM product for asthma; Oculus began selling its Dermacyn™ wound treatment product in China; Sinovac Biotech launched the 2008-09 version of its seasonal flu vaccine, Anflu®; and Genesis Pharma booked $12 million in new orders, most of them for its new flu product.  More details...

Stock Symbols: (NYSE: TCM) (AMEX: CSY) (OTCBB: TYNP) (NSDQ: OCLS) (AMEX: SVA) (OTCBB: GNPH)

China Sky One Medical, with its near-constant barrage of press releases, sometimes seems like an overactive child who always demands attention. On the other hand, the company’s insistent press release schedule is understandable because the company is growing rapidly, its finances are in good order, but investors don’t seem to be paying attention. Today, the company announced that its Heilongjiang Tianlong Pharmaceutical subsidiary has completed its R&D on 26 new drugs and submitted the drugs to the SFDA for approval. More details...

Stock Symbol: (AMEX: CSY)

Bridge Labs announced the FDA accepted its China-developed data for review; Simcere Pharma reported positive interim results from a Phase IV trial of its cancer drug Endu; Roche's Xeloda was granted SFDA approval for gastric cancer, an additional indication; Huifeng Bio-Pharmaceutical Tech will assume control of a medical device company; US-based NeoStem, Inc. placed $1.25 million worth of units with RimAsia Capital Partners; Mindray Medical reported a very solid Q2, the first quarter that reflected its acquisition of Datascope patient monitoring business; Genesis Pharmaceuticals moved higher after completing a 40-to-1 reverse stock split; and China Sky One Medical will list on the NASDAQ Global Market, after just three months on the AMEX. More details...

Stock Symbols: (NYSE: SCR) (OTC Pink Sheets: RHHBY) (OTCBB: HFGB) (AMEX: NBS) (NYSE: MR) (OTCBB: GNPH) (AMEX: CSY)

China Sky One Medical will list its shares on the NASDAQ Global Market. The company’s stock will begin trading on the new exchange on Monday September 15, 2008 under the symbol CSKI. More details...

Stock Symbol: (AMEX: CSY)

Last week was the high water mark for earning reports from China life science companies. WuXi PharmaTech saw a very solid 80% increase in revenues and 134% jump in net income, though questions remain about its AppTec acqusition; American Oriental Bioengineering announced a huge acquisition and higher revenues; Sinovac Biotech enjoyed a substantial increase in Q2 revenues helped by a one-time purchase for earthquake victims; China Sky One Medical detailed excellent Q2 performance and the projects that will keep the company on a growth path; BMP Sunstone reported a very positive Q2 thanks to the Sunstone acquisition; 3SBio Inc. said revenues rose but net income fell; the revenues for Benda Pharmaceutical’s gene-therapy cancer drug slipped though overall revenues were higher; Tongjitang Chinese Medicines  continues to be hurt by counterfeit versions of its flagship product; China Medical Technologies placed $240 million in 4% convertible senior notes, together with an unusual shorting stratagem; China Sky One Medical developed a nasal spray for rheumatic disease; and Schering-Plough  bought in the 45% of its majority-owned China JV that it did not already own.  More details... 

Stock Symbols: (NYSE: WX) (NYSE: AOB) (AMEX: SVA) (AMEX: CSY) (NSDQ: BJGP) (NSDQ SSRX) (OTCBB: BPMA) (NYSE: TCM) (NSDQ: CMED) (NYSE SGP)

China Sky One Medical, with its near-constant barrage of press releases, sometimes seems like an overactive child who always demands attention. On the other hand, the company’s insistent press release schedule is understandable because the company is grow[More...]

China Sky One Medical, Inc.sells over-the-counter nutritional supplements and herb based pharmaceutical and medicinal products.  It is a microcap stock with no debt, and high insider ownership that sports a forward P/E of 5.39.  P/CF is 9.  The 5-year avgs. of operating margins is 29%.  Sales in the most recent quarter increased 62% over the same quarter a year ago.  ROA and ROE are 40 and 46 respectively.  You can't find growth like this in the U.S.  If you do, you certainly won't find it for this cheap.

China Sky One Medical, Inc. released a very positive Q2 earnings report that also beat analysts’ expectations. Revenues increased 62% to $23.7 million, and net income tjumped 92% to $8.1 million or 50 cents per diluted share. Those results were higher than street estimates of $19.5 million and 37 cents per share. In addition to the numbers, China Sky One took pains to point to a number of company accomplishments during the quarter. More details... Stock Symbols: (AMEX: CSY)[More...]

China Sky One Medical reported that it has 11 new drugs in clinical trials, seven of them administered by injection. The clinical trials... [More...]

China Sky One Medical, Inc. received production approval for three injected products, including a propyl gallate... [More...]